Myeloid Leukemia

298 Index
management, 128
AML, see Acute myeloid leukemia
AML1–ETO fusion,
frequency in acute myeloid
leukemia, 149
prognosis, 149
reverse transcription-polymerase
chain reaction,
control gene, 152, 160
data analysis, 157, 158, 160
materials, 150
minimal residual disease
monitoring,
competitive polymerase chain
reaction, 154
control gene, 154
overview, 152–154
real-time quantitative
polymerase chain reaction,
154–156, 160
qualitative analysis, 151, 152, 160
quality control, 158, 159
real-time quantitative polymerase
chain reaction,
EAC protocol, 50, 51
primers, 49
reverse transcription, 151, 160
RNA extraction, 150, 151, 160
Antibody microarray, see Dotscan
microarray
APL, see Acute promyelocytic
leukemia
Arsenic trioxide, acute promyelocytic
leukemia management, 128
B
Banding, see G-banding
BCR–ABL fusion,
breakpoints, 72
fluorescence in situ hybridization,
interpretation and reporting, 111–
113
materials, 111, 112
minimal residual disease
detection, 108, 111
probes, 108–110
prognostic value, 108, 109
gene products, 107, 108
mutation and imatinib mesylate
resistance,
detection of mutations,
materials, 96, 97
semi-nested polymerase chain
reaction, 95–102
sequencing reaction and
analysis, 99, 100, 102–104
overview, 94, 95
Philadelphia chromosome, 69, 72,
85, 93, 96, 101, 107
qualitative reverse transcriptionpolymerase
chain reaction,
atypical transcripts, 82, 83
p210 transcripts, 83, 84, 90
real-time quantitative polymerase
chain reaction,
amplification reactions, 80–82, 85
control gene, 80, 85
interpretation, 82, 85, 87, 89
materials, 72–75
plasmid standards,
cloning, 78, 79
dilutions, 79, 84, 85
polymerase chain reaction, 78
primers and probes, 80, 85
principles, 70
quality control samples, 79, 80
RNA extraction, 75, 76
treatment response monitoring, 70
Bone marrow,
culture and harvest,
materials, 16, 21
overnight culture, 18, 22, 23
synchronization, see Cell
synchronization
transplantation chimerism analysis,
see Chimerism testing